more_reports

Seeking Formulation of New Drug, Biopharma Co. Signs LOI

Research Report
  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) is seeking a novel formulation or drug delivery modalities that could modify the pharmacokinetics of its anti-cancer drug kt3283 to be more tumor targeted, noted a Leede Financial Inc. report.
Tags: Biotechnology / Pharmaceuticals

Healthcare Firm Targets Alzheimer's With Technology Breakthrough

  ()
Healthcare company Algernon Health (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) rebrands and unveils plan to open brain-specific PET scanning clinics in North America to meet rising demand for Alzheimer's diagnostics. Read more to learn how this shift positions the company at the center of a growing medical need.
Tags: Biotechnology / Pharmaceuticals

New Remission Data on MG Patients Compelling

Research Report
  ()
Kyverna Therapeutics Inc.'s (KYTX:NASDAQ) KYV-101 cell therapy drives a 15-month and longer remission in three patients treated on a compassionate use basis, noted an H.C. Wainwright & Co. report.
Tags: Regenerative Medicine

Cell Therapy Firm Kyverna Advances U.S. Phase 3 MG Trial

  ()
Kyverna Therapeutics Inc. (KYTX:NASDAQ) unveiled the design of its U.S. registrational Phase 3 trial for KYV-101 in myasthenia gravis during a Key Opinion Leader event, following ≥ 15-month remission data in Germany. Read more to see what sets this trial apart.
Tags: Biotechnology / Pharmaceuticals

Biopharma Firm Accelerates AI-Driven Cancer Drug Discovery in Canada

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) secured fresh funding, advanced preclinical PARP and ATR programs, and leveraged exclusive AI platforms to target DNA-repair pathways. Read more for insight into its expanding role in precision oncology.
Tags: Biotechnology / Pharmaceuticals

Healthcare AI Company Rebrands as Rocket Doctor AI to Pursue Growing Market Opportunities

  ()
Treatment.com AI Inc. has rebranded and reincorporated as Rocket Doctor AI (AIDR:CSE; TREIF:OTC; 939:FRA) to reflect the integration of its proprietary AI-driven Global Library of Medicine (GLM) with the recently acquired Rocket Doctor Inc. Read why one analyst calls part of the company's offerings "Shopify for physicians."
Tags: Healthcare ServicesTechnology

AI Healthcare Stock Showing Signs of a Base Breakout

Contributed Opinion
  ()
John Newell of John Newell & Associates explains why he thinks Rocket Doctor AI (AIDR:CSE; TREIF:OTC; 939:FRA) is a Speculative Buy.
Tags: Life Sciences Tools & Diagnostics

Co.'s Graphene Used in New Screening Test for Lung Cancer

  ()
HydroGraph Clean Power Inc.'s (HG:CSE; HGRAF:OTCQB; M98:FSE) patented, high-purity material has applications in healthcare, as in this case, but also in numerous other industries. Read on to learn why some experts say this company could be a future 100-bagger.
Tags: Life Sciences Tools & DiagnosticsBattery Metals

Medical Co.'s New Joint Venture Could Expand Co.'s Footprint

Research Report
  ()
Leede Financial Inc. analyst Dr. Douglas Loe gave this company a Buy rating.
Tags: Medical Devices

Canadian Pharmaceutical Company Discovers Breakthrough Cardiovascular Treatment

  ()
Clinical-stage life sciences company Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) announces topline results from its Phase II clinical study involving patients with acute myocarditis. Read why analysts like this pharmaceutical stock.
Tags: Biotechnology / Pharmaceuticals

Pharmaceutical Company Discovers Breakthrough Heart Treatment in Canada

Research Report
  ()
Top-line results from Cardiol Therapeutics' (CRDL:TSX; CRDL:NASDAQ) ARCHER study for Acute Myocarditis are quite promising, writes Roth Capital Partners Analyst Jason Wittes in an updated research note.
Tags: Biotechnology / Pharmaceuticals

Biotech Announces Topline Results From Cardiovascular Drug Trial

Research Report
  ()
Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) Analyst Brandon Folkes reviews Cardiol Therapeutics Inc. after it announced the topline results from its Phase II ARCHER trial of CardiolRx in acute myocarditis.
Tags: Biotechnology / Pharmaceuticals

Canadian Pharma Finds Promising Cardiovascular Breakthrough

Research Report
  ()
Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) reports headline Phase II data from its 109-patient acute myocarditis study, known as the ARCHER trial. Read to see how one analyst rates the stock.
Tags: Biotechnology / Pharmaceuticals

Cleantech/Life Sciences Co. Advances Products in Q2/25

Research Report
  ()
BioLargo Inc. (BLGO:OTCQX) enters into several agreements, forms partnerships and receives third party product validation, noted an Oak Ridge Financial report.
Tags: Alternative - CleantechMedical Devices

Clean Tech Firm Making Important PFAS Breakthrough

  ()
Clean technology company BioLargo Inc. (BLGO:OTCQX) president and chief executive office shares a mid-year update on the company's achievements so far this year, along with insights into its future prospects through a letter to shareholders.
Tags: Alternative - CleantechTechnologyBattery MetalsBiotechnology / PharmaceuticalsSpecial Situations

Cancer Drug Developer Finds Potent Hits With AI in British Columbia

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) taps machine learning to zero in on novel cancer therapies. Read more about the AI engine driving this high-stakes discovery.
Tags: Biotechnology / Pharmaceuticals

Expert Investing Ideas

Streetwise Reader Icon Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Pancreas Cancer Becoming Top Focus for Biotech Co.?

Research Report
  ()
Oncolytics Biotech Inc. (ONCY:NASDAQ; ONC:TSX) published survival data for the use of its immunotherapy pelareorep in pancreatic cancer, and these support the view that this indication should be primary, noted a Leede Financial Inc. report.
Tags: Biotechnology / Pharmaceuticals

Biotech Firm Clears Major U.S. Trading Hurdle

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) just gained DTC eligibility, opening the door for faster U.S. trades and broader investor access. With AI-driven cancer drugs in development, analysts are taking notice. Read more to find out why.
Tags: Biotechnology / Pharmaceuticals

Biotech Partnership to Revolutionize Diabetes Treatment

  ()
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) announces a collaborative research agreement with Eledon Pharmaceuticals Inc. to assess Eledon's immunosuppressive drug in Sernova's ongoing trials of its cell pouch biohybrid organ for patients with Type 1 diabetes (T1D).
Tags: Biotechnology / Pharmaceuticals

Biotech Enters Agreement with Co. Behind Tegoprubart

Research Report
  ()
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) likely will use this new monoclonal antibody as an immunosuppressant in its Phase 1/2 trial's Cohort C instead of previously used tacrolimus, noted an H.C. Wainwright & Co. report.
Tags: Regenerative MedicineMedical Devices

AI Healthtech Firm Partners with EngageWell and CVS Health Foundation on NYC Senior Care Initiative

  ()
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) launches virtual screening for older adults in NYC, backed by US$1M from CVS Health Foundation, as it scales AI tools and patient reach. Read more about how this initiative is helping expand access to care and driving growth in virtual health innovation.
Tags: Biotechnology / Pharmaceuticals